Trials / Completed
CompletedNCT03483324
Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation
A Phase 1 Open-Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Angiocrine Bioscience · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
A phase 1b, open label, multi-center trial of AB-110 in adults with hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia (MDS) undergoing cord blood transplantation. Subjects will receive unmanipulated cord blood (UCB) and AB-110 expanded CD34 enriched hematopoietic progenitor cells (HSPC).
Conditions
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia in Remission
- Myelodysplastic Syndromes
- Other Acute Leukemias
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Unmanipulated Umbilical Cord Blood (UCB) | Human leukocyte antigen (HLA) matched umbilical cord blood |
| BIOLOGICAL | AB-110 | Expanded cord blood stem cells and engineered human endothelial cells |
Timeline
- Start date
- 2018-04-24
- Primary completion
- 2020-12-21
- Completion
- 2022-01-31
- First posted
- 2018-03-30
- Last updated
- 2022-05-31
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03483324. Inclusion in this directory is not an endorsement.